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Background: Few data concerning the oxidative stress (OS) in plasma during the entire menstrual cycle of
eumenorrheic women are available.
Methods: OS was assessed in 20 healthy volunteers during the phase of the menstrual cycle by determining the
plasmatic hydroperoxides levels (d-ROMs test). The assessment was performed every three days, starting from the
first day (t1) up the end of the menstrual phase (t27). Concomitantly, the estrogen (E2) and progestin (P4) levels
were determined at the same time intervals.
Results: From a base value (t1) of 284 +/− 38.0 CARR.U., which is essentially within the normal range (<300
Carratelli units or CARR.U.), the OS levels progressively increased to 378 +/− 115 CARR.U. at t15, and then slightly
decreased over the subsequent time but with average values >300 CARR.U. Analysis of the E2 levels showed that
the maximum OS values were noticed near the estrogen peak, while remaining above the base levels, and then
decreased during the progestin phase until returning to normal at the end of the menstrual cycle.
Conclusions: It may concludes that the healthy women go into OS for 2/3 of the menstrual cycle.
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Few data on the variation of oxidative stress across the
menstrual cycle in eumenorrheic women have been pub-
lished [1,2] and no statistically significant differences
have been detected on markers such as MDA and lino-
leic peroxidation derivatives. The markers analyzed were
related exclusively to lipids peroxidation, whereas the
condition of oxidative stress is affecting many other
compounds such as proteins, DNA and sugars. These
derivatives taken all together can give a more sensible
picture of OS, as it is the case of the hydroperoxides
levels in plasma which allow a more complete although
nonspecific evaluation of OS [3].
Basing the analysis on the local concentration of GSH
(reduced glutathione), GSSG (oxidized glutathione),
GSHpx (glutathione peroxidase enzyme) as well as MDA
(malonyldialdehyde), Serviddio and colleagues were able
to evaluate the change in the oxidative conditions [1]
with regard to the menstrual cycle phases. These* Correspondence: finco.annarosa@libero.it
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reproduction in any medium, provided the orconditions were then correlated with the estrogen (E2)
and progestin hormone levels (P4), as well as the
luteinizing hormone (LH) and follicle-stimulating hor-
mone (FSH).
This data shows that the peak OS phase occurs in the
central phases of the cycle (late follicular phase and early
luteal phase), or rather at the time of ovular maturation
and possible implantation. This phase occurs with: a) an
increase in the production of GSHpx; b) a reduction in
the GSH; c) an increase in the GSSG; d) a substantial
stability of the MDA.
This all seems to indicate that the increase in OS cor-
responds to a compensation by the antioxidant systems
so that the MDA concentration (index of lipid peroxida-
tion) remains constant; in other words, the oxidation/
antioxidant protection system tends to be equilibrated
for the entire menstrual cycle. The peak OS will corres-
pond to the E2 and LH peaks, while the P4 peak seems
to correspond with an OS recovery phase.
The increase in the GSHpx actually corresponds to an
increase in the oxidation of GSH; therefore, an increase
in the enzyme that “consumes” the GSH to transforml Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Cornelli et al. Reproductive Biology and Endocrinology 2013, 11:74 Page 2 of 6
http://www.rbej.com/content/11/1/74the hydrogen peroxide (H2O2), corresponds to a reduc-
tion in the GSH itself, with a resulting increase in the
GSSG. This all means OS; it is therefore incorrect to
consider GSHpx (any type 1 or 3) as an index of antioxi-
dant capacity, since it is caused by an increased need to
use GSH to confront the OS.
When the GSHpx system, SOD (superoxide dismu-
tase) and CAT (catalase) in the erythrocytes are simul-
taneously analyzed over the course of the menstrual
cycle [4], the levels of GSHpx increase in the late follicu-
lar phase and initial luteal phase with respect to the
other phases, while the SOD and CAT levels remain
essentially constant with no significant cycle dependent
changes. Analysis of the relationships with the levels of
E2 indicate that the levels of GSHpx are time related; in
extreme synthesis, the increase of one is contemporan-
eous to the increase of the other. On the contrary, the
plasmatic levels of FSH, LH, P4, testosterone and andro-
stenedione do not show any time related relationships
with those from the erythrocytic GSHpx and no signifi-
cant variation in SOD and CAT levels.
From what has been observed, it seems that the isolat-
ing action of the E2 is not the antioxidant action, but is
exactly the opposite [5], which will correspond to the
cellular activation needed for the increased energy pro-
duction from the secretion phase, with a subsequent in-
crease in the production of reactive species such as
superoxide (O2
•), H2O2 and hydroxyl radicals (OH
•).
If the ovule is not fertilized, the luteal phase is also
characterized by an increase in cellular activity and the
proliferation of tissue, which precede the end of the
cycle, returning the uterus' mucous membrane to the
initial cycle condition with the menstrual flow. Locally,
the luteal phase occurs with different activations with re-
spect to the estrogen phase, for example, the increase in
mucous’ viscosity or in vascular components, and so on.
It remains, in any case, similar in terms of oxidation, be-
cause it is proliferative phase too, although with different
types of final products (mucous, vascular efficiencies).
This phase is dominated by the production of P4, which
adds to that of the E2, and is therefore the highest com-
bined expression of estrogen-progestin steroids.
The plasmatic conditions of OS have never been con-
tinuously examined during all phases of the menstrual
cycle; it is therefore unknown if that which occurs
locally or at the erythrocyte level is also expressed in a
similar way in the plasma.
The purpose of this research is to assess the levels of
oxidative stress during the normal menstrual cycle. OS
condition has been measured by determining the plas-
matic hydroperoxides thought d-ROMs test [6,7].
The most common markers for the evaluation of OS
are MDA (TBARS), isoprostanes, carbonylated proteins
and oxidized DNA. There is no current consensus aboutwhich method is the most useful, reliable and specific
for the oxidative insult. The suggestion given by some
authors is to use more than one test for a more
complete evaluation. The choice of hydroperoxides
measurement belongs to the consideration that most of
the proteins, DNA and lipids once oxidized are
transformed into hydroperoxides (ROOH). These com-
pounds are slowly reactive and can transfer the oxidative
stress across the cells [8].
A comparative analysis has been done among the most
common markers [3] reaching the conclusion that
d-ROMs test seems to be the most reliable.
Methods
20 eumenorrheic female volunteers were enrolled after a
written and informed consent. The study received also
an institutional review board approval from the ethics
committee of the University of Chieti. They were appar-
ently healthy volunteers, most nulliparous (14 of 20), not
following any type of contraceptive therapy. The use of
any therapy with dietary supplements was considered
grounds for exclusion, as was the excessive consumption
of alcohol (>3 alcohol units or AU; considering 1
AU =120 mL of wine or 330 mL of beer or 40 mL of
spirits), tea (>3 cups/day), coffee (>3 cups/day), choc-
olate (>50 g/day). The exclusion criteria was also ex-
tended to women with a history of surgery, with
gynecological diseases with recent infections or with
restrictive diet.
Analysis of oxidative stress (OS)
The analysis of the OS condition during the menstrual
cycle was assessed on the basis of the Reactive Oxygen
Metabolites-derived compounds (d-ROMs) test [4,5]
which is used to determine the levels of hydroperoxides
in plasma (expression of lipid peroxidation). The analysis
was assessed on patients fasting since the evening before
the exam.
The blood was taken by pricking the finger and collecting
0.15-0.2 mL of blood in a heparinized microcuvette.
The microcuvette was immediately centrifuged (6000 g
for 1 min) in order to isolate the plasma on which the
test is performed, within and no longer than 2 h from
being drawn. The levels of hydroperoxides were quanti-
fied in Carratelli Units (CARR.U.; 1 CARR.U. = 0,08 mg
H2O2/100 mL).
The normal values are <300 CARR.U. The test was
applied from the first day from the end of the menstrual
flow (t1 or start of the new menstrual cycle) and then
every three days (indicated as t1,t3, tn…t27), for the rest of
the cycle, up until the time the next menstrual flow
completely stopped. The time progression of the OS
during the menstrual cycle can be defined in this
manner.
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Only 10 volunteers out of 20 patients accepted to repeat
the venous blood sampling and on these patients the
protocol also included the evaluation of the E2 level at
times t6 , t9, t12, t15, t18, t21, as well as the levels of P4 at t12 ,
t18, t21, t24, in order to determine the correlation of OS
with the secretion and luteal phases of the menstrual cycle.
The levels of E2 and P4 were determined using com-
mercially available kits (Estradiol: Catalog No KE2D1;
Progesterone: TKPG1; Inter Medico Markham, Ontario-
Canada). The detection limits for these tests were 5 pg/
mL for E2 and 0.1 ng/mL for P4, with variation coeffi-
cients of 13.1% for E2 and 6.5% for P4. The blood for
these hormones (2 aliquots of 5 ml each) was taken from
the arm vein in heparinized test tubes. All blood with-
drawals were done in the morning between 8:00 and
9:30 a.m. with analytical determination within that same
day. The volunteers were told to avoid eating large
amounts of food the night before the laboratory tests.Statistical analysis
From previous experience on d-ROMs test [5] for α = 0.05
and 1-β=0.9 a sample of 12 cases is sufficient to discrimin-
ate groups with a power >0.9. The average values and dis-
persion parameters (SD) were calculated on all data. The
comparison between the base values and those at the vari-
ous observation times were done using Randomized Block
Design Anova, the multiple comparisons were calculated
using “Dunnett’s Two-Sided Multiple Comparison Test vs
t1 for d-ROMs test, vs t6 for E2 and vs t12 for P4. The rela-
tionships between the d-ROMs test and E2 or P4 levels
based on the parametric correlation test.Results
Despite the limited number of patients (n = 20), all vol-
unteers finished the study. The general characteristics of
the volunteers are reported in Table 1. The OS increase
(see Table 2) begins on average between t6 and t24, and
the hydroperoxide levels return to the base values from
the start of the new cycle at t27.
The concomitance of the maximum increase of hydro-
peroxides corresponds to a delay from three to six days




Age (yrs) 30.8 +/− 5.66
Weight (Kg) 63.2 +/− 6.66
Height (m) 1.67 +/− 0.07
BMI (Kg/m2) 22.6 +/− 1.58levels instead seems to cause a slight reducing effect on
the OS when at its hematic peak (t21) but not before.
As can be seen from the average values, the increase
in the CARR.U. with respect to those from the start of
the cycle reach the condition defined as OS (>300
CARR.U.) from t12 to t24.
With regard to that noted in the literature [9], the E2
levels reach a peak between t9 and t12 while the P4 levels
significantly increase between t18 and t21. Our evalua-
tions extended to t24, which is the moment when the in-
flection of the P4 levels was observed.
No correlations between the d-ROMs test and E2
levels were observed; this seems to indicate that the in-
crease in systemic oxidation is not determined by just
E2, but also by other factors that could not be identified
at our experimental conditions (hypothetically referring
to levels of LH, FSH, relaxin, etc.).
Discussion
Browne et al. [2] end up with the conclusion that no sig-
nificant variation of the OS markers can be shown dur-
ing the menstrual cycle. However the data were limited
to 9 cases with a large variation of BMI (ranging be-
tween 20.9 and 34.7) and also the inter-individual coeffi-
cient of variation of the OS markers were very high
(from 30 to 56%). This means that the power of the ana-
lysis was very limited. In previous trials the coefficient of
variation of d-ROMs with almost a similar sampling (12
cases) was < 10%, as a consequence we may suppose that
the hydroperoxides measure can be more reliable and
early in detecting the condition of OS.
From that observed, a woman is in an OS condition
for a good portion of the menstrual cycle, starting near
her estrogen peak and hydroperoxides tend to decrease
slightly when progestin hormone increases, which how-
ever does not allow normal levels to be reached. This
fact puts all of the findings made up to now into ques-
tion in terms of OS in pre-menopausal women.
Therefore, the OS indexes for fertile women should be
reviewed in relation to the menstrual period.
If OS relates to a particular moment of the menstrual
cycle, its correlations with the various pathologies
should be corrected in relation to this "oxidative cyclic-
ity". Obviously, that seen for lipid type hydroperoxides
may not apply to the other OS markers, such as
isoprostanes or DNA oxidation products (8-OHdG for
example) and proteins (carbonylated proteins); neverthe-
less, at least in part, some of these derivatives also have
a hydroperoxide component.
All the hypotheses for the reason for this cyclic algo-
rithm are to be investigated. We know that both the
estrogen and the progestin phases have an activation
phase; the proliferation phase involves an increase in the
production and consumption of energy, which continues
Table 2 d-ROMs test, E2, P4 values at various times in healthy volunteers (average ± SD)
t1 t3 t6 t9 t12 t15 t18 t21 t24 t27
d-ROMs CARR.U. 284 273 284 299a 336a 378a 326a 315a 323a 276
+/− +/− +/− +/− +/− +/− +/− +/− +/− +/−
38.0 47.0 34.6 31.3 66.8 115.6 66.4 56.3 51.1 44.8
E2 pg/mL 99 222
b 195b 134b 157b 126
+/− +/− +/− +/− +/− +/−
33.7 34.2 39.9 36.2 36.9 38.4
P4 ng/mL 1.7 6.3c 13.0c 5.9c
+/− +/− +/− +/−
0.54 3.0 6.2 3.8
aDunnett’s Two-Sided Multiple Comparison Test, p < 0.05 tn Vs t1.
bDunnett’s Two-Sided Multiple Comparison Test, p < 0.05 tn Vs t6.
cDunnett’s Two-Sided Multiple Comparison Test, p <0.05 tn Vs t12.
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(vascular space) with a substantial production of nitric
oxide (NO•).
Nitric oxide, besides having a radical nature, is an im-
portant mediator for vasodilatation, the relaxation of the
myometrium, anti-aggregation action and angiogenic
stimulation which occurs by means of VEGF (vascular
endothelial growth factor); this in turn stimulates NO
synthase (NOS) [10], indicating that the NO• is trying to
maintain its level with the self-induction of NOS.
This synthesis, even though it occurs in all menstrual
phases as eNOS (endothelial) and iNOS (induced),
increases slightly with progestin stimulus [11]. This
entire system must be counterbalanced in a very precise
manner.
Locally, there is also an increase in the SOD that coin-
cides with this increase in the synthesis of NO•. SOD, car-
rying out the dismutation of O2
•(superoxide), to form
H2O2 +O2, inhibits the NO
• + O2
• reaction that tends to
produce the ONOO- ion (peroxynitrite) which, besides
having a strong oxidizing strength, removes NO• and
limits its availability. Nevertheless, the high level of avail-
able NO• can however react with O2
• , since the reaction
between the two is by far the fastest in the body (1 ×
10-9 sec) and can generate OS. It is therefore not surpris-
ing that the vectorial result of the antioxidant and oxidant
production, action of the progestin phase stabilizes on an
OS scale. That which occurred in terms of d-ROMs values
was seen in all cases analyzed, therefore the data indicat-
ing that OS conditions are present for approximately 2/3
of the menstrual cycle phases is considered “solid”.
The connection between OS and the E2 and P4 levels
is also confirmed by the previous observations, since we
know that the levels of hydroperoxide in women taking
birth control pills increase significantly [12,13]. This fact
must clearly be confirmed through specific studies, but
tends to discredit the hypothesis that exogenous estro-
gens have an antioxidant action [14,15].The opposite instead seems to be true. Hypothetically
speaking, the action of the estrogens may be similar to
that which occurs during exertion [16]. In this condition,
the LDLs are oxidized but are also more easily up-taken
by the blood receptors, or kept under control and par-
tially "diminished" by the muscular antioxidant systems.
Same has been described by other authors [17] that sug-
gest estradiol promote the oxidation of LDL and pro-
motes their clearance from the liver. If however their
quantity increases, even at the rate of an inefficient
antioxidant system, they are subject to vascular uptake
(sub-endothelial) triggering the atherosclerotic inflam-
matory process. The sub-endothelial will in fact be
subject to the action of myeloperoxidase (MPO), which
are oxidant-producing enzymes.
This justifies the reduction of the cholesterol and the
LDL in premenopausal women, which should not be
interpreted as greater efficiency of the LDL blood recep-
tors, but as an increased uptake of LDL thanks to their
partially oxidized condition (keep in mind that there is a
minimum repairable oxidation limit above which triggers
the macrophage reaction).
This oxidative balance, already modified under physio-
logical conditions of normal estrogen/progestin secre-
tion (thus during a normal menstrual phase) can lead to
an excess of oxidant production when birth control (BC)
therapy is followed. This phenomenon is understandable,
since any oral administration of estrogen/progestin
generates a hematic peak in both, which is not on a
physiological scale and therefore the OS can become
permanent.
It belongs to previous observations that anti-proteases
in general are more sensible than proteases to oxidation,
due to presence of an higher amount of methionine in
anti-proteases [18]. Since some proteases such as throm-
bin are pro-coagulant whereas anti-proteases are anti-
coagulant (serpins), the tendency of an increase of OS
will be a pro-thrombotic status.
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nomena, besides the maintaining of the vascular patency
of the endometrium and its regular distribution of blood,
could originate from the presence of a special peptide
hormone in women, relaxin (RLX), which could act as a
powerful stimulant for the antioxidant systems [19].
Relaxin is a polypeptide with a MW of 6 KDa and is
composed of two peptide chains stabilized both intern-
ally and between each other by S-S bridges [19]. It is
mainly secreted by the corpus luteum and strategically
inhibits alterations in the endometrial flow, to prevent
ischemia and reperfusion phenomena, both during the
cycle's proliferation phase and then during the eventual
pregnancy. The ischemia and reperfusion phenomenon
causes OS, both by the production of ROS and by
chemotactic stimulation.
The action of the RLX works by over-regulating the
iNOS and eNOS, besides the angiogenesis in particular -
but not exclusively - in the endometrium; this stimulus
occurs in both arterial and venous vessels (thus also in
vessels without smooth muscle). RLX is active at
nanomolecular concentrations, which therefore can be
obtained during the endometrial phases by the ovular
implantation and by pregnancy. The angiogenic action is
typical of RLX and occurs through the release of VEGF
and also bFGF (basic fibroblast growth factor).
An important aspect of the action of RLX is the inhib-
ition of the endothelial adhesiveness of the inflammatory
cells (lymphocytes, macrophages) as well as platelet
aggregation.
Overall, RLX substantially influences the perfusion and
hematic distribution in the endometrium, giving it
the ideal flow conditions and performing an anti-
inflammatory and anti-thrombotic action and opposes
the effects of OS; it could therefore perform a protective
action against OS.Conclusions
Healthy eumenorrheic women go into OS for 2/3 of the
menstrual cycle. Oxidative stress is however a physio-
logical condition for women of child-bearing age. This
implies that an over-regulation of the OS defense mech-
anisms is also present. Therefore, all the OS markers
should be studied during the various phases of the cycle
and parameterized to this phenomenon.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Research was designed by CU; BG and MRC were responsible for the
volunteers selection and for the E2 and P4 determination. The d-ROMs on
plasma samples was carried out by FA at the Cor. Con. International Srl
Research Labs, that provided all the analytical reagents also. All authors read
and approved the final manuscript.Acknowledgments
We are profoundly grateful to Professor Martino Recchia for the statistical
analysis of the data. No financial or contractual agreement that may cause
conflict of interest or be perceived as causing are in place. No works are
being concurrently published or reviewed that are relevant to the
manuscript. The corresponding author and all of the authors have read and
approved the final submitted manuscript. No portion of this work has been
or is currently under consideration for publication elsewhere. No portion of
this manuscript, other than the abstract, has been published or posted on
the internet.
Author details
1Loyola University School of Medicine-Chicago, Chicago, USA. 2University of
Chieti, Chieti, Italy. 3Cor Con. International Srl Res Department, Parma, PR,
Italy.
Received: 19 April 2013 Accepted: 29 July 2013
Published: 2 August 2013
References
1. Serviddio G, Loverro G, Vicino M, Prigigallo F, Grattagliano I, Altomare E,
Vendemiale G: Modulation of endometrial balance during the menstrual
cycle: relation with sex hormones. J Clin Endocrinol Metab 2002, 87:2843–2848.
2. Browne RW, Bloom MS, Schisterman EF, Hovey K, Trevisan M, Wu C, Liu A,
Wactawski-Wende J: Analytical and biological variation of biomarkers of
oxidative stress during the menstrual cycle. Biomarkers 2008, 13:160–183.
3. Cornelli U, Belcaro G, Finco A: The oxidative stress balance measured in
humans with different markers, following a single oral antioxidants
supplementation or a diet poor of antioxidants. J Chem Dermatol Sci Appl
2011, 1:64–70.
4. Massafra C, Gioia D, De Felice C, Picciolini E, De Leo V, Bonifazi M, Bernabei
A: Effects of estrogens and androgens on erythrocyte antioxidant
superoxide dismutase, catalase and glutathione peroxidase activities
during the menstrual cycle. J Endocrinol 2000, 167:447–452.
5. Santanam N, Shern-Brewer R, McClatchey R, Castellano PZ, Murphy AA, Voelkel
S, Parthasarathy S: Estradiol as an antioxidant: incompatible with its
physiological concentrations and function. J Lipid Res 1998, 39:2111–2118.
6. Cesarone MR, Belcaro G, Carratelli M, Cornelli U, De Sanctis MT, Incandela L,
Barsotti A, Terranova R, Nicolaides A: A simple test to monitor oxidative
stress. Int Angiol 1999, 18:127–130.
7. Cornelli U, Terranova R, Luca S, Cornelli M, Alberti A: Bioavailability and
antioxidant activity of some food supplements in men and women using
the d-ROMs test as a marker of oxidative stress. J Nutr 2001, 131:3208–3211.
8. Brigelius-Flohè R, Flohé L: Basic principles and emerging concepts in the redox
control of transcription factors. Antioxid Redox Signal 2011, 15:2335–2381.
9. Loose DS, Stancel GM: Estrogens and Progestins. In Goodman & Gilman's
the pharmacological basis of therapeutics. 11th edition. Edited by Brunton LL,
Lazo JS, Parker KL. New York: McGraw-Hill; 2006:1541–1571.
10. Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun CO, Buerk DG,
Huang PL, Jain RK: Predominant role of endothelial nitric oxide synthase
in vascular endothelial growth factor-induced angiogenesis and vascular
permeability. Proc Soc Acad Sci USA 2001, 98:2604–2609.
11. Cameron IT, Campbell S: Nitic oxide in the endometrium. Human Repr
Update 1998, 4:565–589.
12. Foidart JM, De Groote D, Claesen J, Gerday C, Balteau B, Pintiaux A, Perrier
d'Hauterive S: Effect of oral contraception with ethiylestradiol and
drospirenone on oxidative stress in women 18–35 years old.
Contraception 2009, 80:187–193.
13. Pincemail J, Vanbelle S, Gaspard U, Collette G, Haleng J, Cheramy-Bien JP,
Charlier C, Chapelle JP, Giet D, Albert A, et al: Effect of different
contraceptive methods on the oxidative status in women aged 40–48
years from ELAN study in the province of Liège- Belgium. Human Reprod
2007, 22:2335–2343.
14. Sack MN, Rader DJ, O Cannon R: Oestrogens and inhibition of oxidation
of low-density lipoproteins in postmenopausal women. Lancet 1994,
343:269–270.
15. Sugioka K, Shimosegawa Y, Nakano M: Estrogerns as natural antioxidants
of membrane phospholipid peroxidation. FEBS 1987, 210:37–39.
16. Shern-Brewer R, Santanam N, Wetzstein C, White-Welkley J, Parthasarathy S:
Exercise and cardiovascular disease a new perspective. Arteriosc Thromb
Vasc Biol 1998, 18:1181–1187.
Cornelli et al. Reproductive Biology and Endocrinology 2013, 11:74 Page 6 of 6
http://www.rbej.com/content/11/1/7417. Chiang K, Parthasarathy S, Santanan N: Estrogen, neutrophils oxidation.
Life Sci 2004, 75:2425–2438.
18. Swaim MW, Pizzo SV: Methionine sulfoxide and the oxidative regulation
of plasma proteinase inhibitors. J Leuk Biol 1988, 43:365–379.
19. Bani D: Relaxin as a natural agent for vascular health. Vasc Health Risk
Manag 2008, 4:515–524.
doi:10.1186/1477-7827-11-74
Cite this article as: Cornelli et al.: Analysis of oxidative stress during the
menstrual cycle. Reproductive Biology and Endocrinology 2013 11:74.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
